JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Teladoc Health (NYSE:TDOC) Stock

Teladoc Health (NYSE:TDOC) had its price target hoisted by research analysts at JPMorgan Chase & Co. from $8.00 to $10.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm currently has a “neutral” rating on the health services provider’s stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 17.37% from the stock’s previous close.

A number of other equities analysts also recently issued reports on the stock. Bank of America raised their price objective on shares of Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Canaccord Genuity Group reduced their price target on shares of Teladoc Health from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Stifel Nicolaus lifted their target price on Teladoc Health from $5.50 to $6.50 and gave the stock a “hold” rating in a report on Thursday. Citigroup reduced their price objective on shares of Teladoc Health from $11.00 to $7.50 and set a “neutral” rating on the stock in a research report on Monday, August 3rd. Finally, Needham & Company LLC restated a “hold” rating on shares of Teladoc Health in a report on Thursday. Five investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $7.77.

Teladoc Health Price Performance

NYSE:TDOC traded down $0.21 during mid-day trading on Friday, reaching $8.52. 8,158,447 shares of the company’s stock traded hands, compared to its average volume of 5,112,266. Teladoc Health has a 12-month low of $4.40 and a 12-month high of $9.89. The firm has a market capitalization of $1.55 billion, a price-to-earnings ratio of -9.91 and a beta of 2.14. The company has a 50 day moving average price of $6.19 and a 200-day moving average price of $6.47.

Teladoc Health (NYSE:TDOC) last announced its earnings results on Wednesday, October 28th. The health services provider reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. Teladoc Health had a negative net margin of 6.27% and a negative return on equity of 11.52%. The firm had revenue of $605.10 million for the quarter, compared to analysts’ expectations of $588.14 million. During the same quarter in the previous year, the business posted ($0.28) EPS. The company’s quarterly revenue was down 3.4% on a year-over-year basis. As a group, analysts forecast that Teladoc Health will post -0.92 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Charles III sold 17,805 shares of the firm’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $6.10, for a total transaction of $108,610.50. Following the sale, the chief executive officer owned 465,535 shares in the company, valued at approximately $2,839,763.50. This trade represents a 3.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 0.70% of the company’s stock.

Institutional Investors Weigh In On Teladoc Health

Large investors have recently made changes to their positions in the stock. Monaco Asset Management SAM acquired a new stake in Teladoc Health during the second quarter worth $26,864,000. Counterpoint Mutual Funds LLC lifted its holdings in Teladoc Health by 1,017.4% during the 3rd quarter. Counterpoint Mutual Funds LLC now owns 1,650,165 shares of the health services provider’s stock worth $9,571,000 after buying an additional 1,502,488 shares during the last quarter. Quantinno Capital Management LP grew its position in shares of Teladoc Health by 128.0% in the 1st quarter. Quantinno Capital Management LP now owns 2,621,378 shares of the health services provider’s stock valued at $14,287,000 after buying an additional 1,471,631 shares during the last quarter. Pale Fire Capital SE lifted its stake in Teladoc Health by 74.8% in the first quarter. Pale Fire Capital SE now owns 3,398,491 shares of the health services provider’s stock valued at $18,522,000 after buying an additional 1,454,288 shares during the last quarter. Finally, Freestone Grove Partners LP acquired a new position in Teladoc Health in the 2nd quarter valued at about $7,338,000. 76.82% of the stock is currently owned by hedge funds and other institutional investors.

More Teladoc Health News

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Q3 results beat expectations. Teladoc reported a loss of $0.15 per share versus the $0.23 consensus loss, while revenue of approximately $605 million exceeded estimates by about 3.3%. Adjusted EBITDA reached roughly $79 million, near the high end of guidance. Teladoc Q3 loss and revenue results
• Positive Sentiment: Cash flow and loss quality improved. Investors responded favorably to stronger free cash flow and adjusted EBITDA, suggesting that Teladoc is making progress on cost control even as revenue declined about 3% year over year. Teladoc stock rebounds as cash flow improves
• Positive Sentiment: BetterHelp’s insurance strategy is gaining traction. BetterHelp generated $32 million in insurance revenue during Q3, and management expects the insurance-related business to reach an annualized run rate of at least $200 million. Teladoc also plans to repurchase convertible notes, potentially reducing financial obligations. Teladoc BetterHelp insurance and convertible notes plans
• Positive Sentiment: Deutsche Bank raised its price target to $11 from $10 and maintained a Buy rating, reinforcing the bullish reaction to the earnings report. Deutsche Bank Teladoc price target update
• Neutral Sentiment: Unusually heavy call-option activity and the stock’s move above its 200-day moving average may amplify momentum, but these are trading signals rather than fundamental improvements.
• Negative Sentiment: Forward guidance remains mixed. Full-year revenue guidance of $2.4 billion matched consensus, but the FY 2026 EPS range of negative $0.95 to negative $0.75 brackets consensus at negative $0.81. Q4 revenue guidance also has a midpoint below analyst expectations, while the EPS range is wider and includes results below consensus.
• Negative Sentiment: Stifel raised its price target to $6.50 but retained a Hold rating, and Needham reaffirmed Hold. These targets remain well below recent trading levels, highlighting valuation and execution concerns. Stifel Teladoc rating

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services and technology designed to connect patients with medical professionals remotely. Through its digital platforms, the company supports a range of healthcare needs, including general medical consultations, mental health services, specialty care, and ongoing management of chronic conditions.

Its offerings include telehealth visits with physicians and other licensed providers, behavioral health services through BetterHelp, and chronic care programs that use digital tools and clinical support to help people manage conditions such as diabetes and hypertension.